No-Fee CE: Myopia Beyond 2025
This course is designed to help readers understand the development of the disease of myopia. The article identifies areas in which clinicians can intervene to slow progression using the latest research evidence from the past year.
By
CARA FRASCO LAI, OD, MS
Nicky Lai, OD, MS
March 1, 2026
Clinical Scorecard: No-Fee CE: Myopia Beyond 2025
At a Glance
Category Detail
Condition Myopia Management Key Mechanisms Parental myopia, reduced time outdoors, low hyperopic reserve, axial elongation. Target Population Children at risk for myopia and those already myopic. Care Setting Optometry and eyecare practices.
Key Highlights
FDA approval of a spectacle lens for myopia control in late 2025. Low hyperopic reserve is the greatest predictive factor for myopic progression. Increased time spent outdoors is associated with reduced risk of myopia onset. A 1-year delay in myopia onset can significantly lower final myopia levels. Emerging research indicates early changes in choroidal thickness may predict treatment efficacy. Guideline-Based Recommendations
Diagnosis
Assess parental myopia and hyperopic reserve. Monitor axial elongation in children. Management
Implement comprehensive myopia management programs. Provide lifestyle recommendations to enhance retinal signaling. Monitoring & Follow-up
Regularly evaluate retinal image quality and axial length. Risks
Children with low hyperopic reserve are at increased risk for developing myopia. Patient & Prescribing Data
Children, particularly those with parental myopia and low hyperopic reserve.
Use evidence-based optical and/or pharmaceutical treatments to optimize retinal growth regulation.
Clinical Best Practices
Encourage increased outdoor time for children. Utilize soft multifocal contact lenses for myopia management. Related Resources & Content
